Age, Biography and Wiki
Calvin A. Grant was born on 1970, is a Calvin Alexander Grant is American ophthalmologist American ophthalmologist. Discover Calvin A. Grant's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is he in this year and how he spends money? Also learn how he earned most of networth at the age of 54 years old?
| Popular As |
N/A |
| Occupation |
N/A |
| Age |
54 years old |
| Zodiac Sign |
N/A |
| Born |
1970 |
| Birthday |
|
| Birthplace |
N/A |
| Nationality |
|
We recommend you to check the complete list of Famous People born on .
He is a member of famous with the age 54 years old group.
Calvin A. Grant Height, Weight & Measurements
At 54 years old, Calvin A. Grant height not available right now. We will update Calvin A. Grant's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.
| Physical Status |
| Height |
Not Available |
| Weight |
Not Available |
| Body Measurements |
Not Available |
| Eye Color |
Not Available |
| Hair Color |
Not Available |
Dating & Relationship status
He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.
| Family |
| Parents |
Not Available |
| Wife |
Not Available |
| Sibling |
Not Available |
| Children |
Not Available |
Calvin A. Grant Net Worth
His net worth has been growing significantly in 2023-2024. So, how much is Calvin A. Grant worth at the age of 54 years old? Calvin A. Grant’s income source is mostly from being a successful . He is from . We have estimated Calvin A. Grant's net worth, money, salary, income, and assets.
| Net Worth in 2024 |
$1 Million - $5 Million |
| Salary in 2024 |
Under Review |
| Net Worth in 2023 |
Pending |
| Salary in 2023 |
Under Review |
| House |
Not Available |
| Cars |
Not Available |
| Source of Income |
|
Calvin A. Grant Social Network
Timeline
Grant was born in 1970 in Washington, D.C., to Jamaican parents, and spent a large amount of his childhood in the Washington Metropolitan Area.
At the age of 21 he attended the University of Pennsylvania School of Medicine where he received the Oliver prize for ophthalmological research.
His earlier research in gene transfer to the retina using adeno-associated viruses was one of the first.
This work was conducted under the Howard Hughes Medical Student Fellowship.
Grant developed the first sustained treatment for ischaemic and non-ischaemic central retinal vein occlusion.
His procedure, called revascularization by anastomotic decompression (RAD), allowed for communication between the blocked superficial retinal venous circulation and the open underlying choroidal circulation.
In a press release issued by ISTA Pharmaceuticals, which has a strong interest in the success of the drug, it was claimed that Grant demonstrated a significant decrease in the number of treatments of ranibizumab (Lucentis) needed for the treatment of choroidal neovascularization secondary to age-related macular degeneration by the concomitant administration of bromfenac (Xibrom).
There was a significant reduction in the number of injections of ranibizumab given to those patients also receiving bromfenac during a six-month period.
ISTA Pharmaceuticals at first claimed that there was no statistically significant visual acuity improvement amongst those receiving bromfenac in addition to ranibizumab, however; they now claim that upon "rigorous review" a significant improvement can be detected.
ISTA Pharmaceuticals states that these results will need to be verified in clinical studies and that bromfenac is not currently approved for the treatment of age-related macular degeneration.
Grant has also become the first to introduce robotic radiosurgery in the treatment of choroidal melanoma.
Grant has had his license indefinitely suspended for a minimum of 6 months and fined $10,000 for performing a surgical procedure below the required standard of care and engaging in unprofessional conduct.
https://idfpr.illinois.gov/content/dam/soi/en/web/idfpr/forms/discpln/2023-07enf.pdf
